Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression [ATAC-Seq]

ABSTRACT: Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression [ATAC-Seq]

PROVIDER: PRJNA549872 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9331570_1.fastq.gz	Fastqsanger.gz
	SRR9331570_2.fastq.gz	Fastqsanger.gz
	SRR9331580_1.fastq.gz	Fastqsanger.gz
	SRR9331580_2.fastq.gz	Fastqsanger.gz
	SRR9331590_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 128

Similar Datasets

Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression

Project description:Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression

| PRJNA549869 | ENA

Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression [RNA-Seq]

Project description:Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression [RNA-Seq]

| PRJNA535506 | ENA

Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression [ATAC-Seq]

Project description:Pygopus2 (Pygo2), a co-activator of Wnt/ β-catenin signaling can also bind H3K4me2/3 and participate in chromatin reading and writing. To investigate the functional relevance of histone binding activity of Pygo2 in malignant progression of breast cancer, we generated a knockin mouse model wherein binding of Pygo2 to H3K4me2/3 was rendered ineffective. Loss of Pygo2-histone binding resulted in smaller, differentiated and less metastatic tumors, at least in part due to a decrease in Wnt/ b-catenin signaling. RNA and ATAC-Seq analyses of tumor-derived cell lines revealed a downregulation of TGFb signaling and an upregulation of differentiation pathways like PDGFR. This also correlated with an increase in luminal cell fate which could be rescued by inhibition of the PDGFR pathway. Mechanistically, we find that Pygo2-histone interaction is important for expression of mir-29 family members to potentiate Wnt/ b-catenin signaling by suppressing Wnt signaling antagonists expression in addition to suppression of PDGFR expression. Collectively, our results demonstrate that histone binding function of Pygo2 is important for driving de-differentiation and malignancy of breast tumors and loss of this binding activates differentiation pathways that lead to decreased tumor growth and metastases. Ablating the Pygo2-H3K4me3 interaction hence might serve as an attractive therapeutic target for breast cancer.

2020-09-08 | GSE133066 | GEO

Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression [RNA-Seq]

2020-09-08 | GSE130330 | GEO

Pygopus2-Histone interaction is important for de-differentiation and breast cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-09-08 | GSE133068 | GEO

Cancer associated fibroblasts play an important role in prostate cancer progression [ATAC-Seq]

Project description:Cancer associated fibroblasts play an important role in prostate cancer progression [ATAC-Seq]

| PRJNA882047 | ENA

Genome wide analysis of important transcription factors and histone modifications for prostate cancer progression

Project description:Genome wide analysis of important transcription factors and histone modifications for prostate cancer progression

| PRJNA612299 | ENA

Macrophage-Tumor Cell Interaction Promotes ATRT Progression and Chemoresistance

Project description:Macrophage-Tumor Cell Interaction Promotes ATRT Progression and Chemoresistance

| PRJNA593820 | ENA

Essai de phase II, randomisé multicentrique, évaluant l’efficacité d’une chimiothérapie standard à base de fluoropyrimidine associée au cétuximab ou au bévacizumab, chez des patients kras sauvage, atteints d’un cancer colorectal métastatique, en progression après une 1ere ligne de traitement avec bévacizumab.

Project description:Primary objectives: Evaluer la survie sans progression (SSP) à 4 mois. Primary endpoints: La survie sans progression (SSP) à 4 mois. La réponse au traitement sera évaluée par l’investigateur selon les critères RECIST v1.1 2009 modifiés tous les 6 semaines et jusqu’à progression de la maladie. Les patients avec des symptômes évocateurs d’une progression de la maladie devront être évalués au plan tumoral au moment de la survenue des symptômes.

| 2526593 | ecrin-mdr-crc

Cancer associated fibroblasts play an important role in prostate cancer progression

Project description:Cancer associated fibroblasts play an important role in prostate cancer progression

| PRJNA882042 | ENA